Search the Site
Follow TheCancerLetter on Twitter
join our mailing list

Enter your name and email address to receive an update when we post new content.

IP Login

 

The Cancer Letter Inc.
PO Box 9905
Washington
DC 20016
Tel: 202-362-1809
Fax: 202-379-1787
publication date: Dec 24, 2015
View a Printer Friendly version of this page, allowing you to print the page. Send a summary of this page to someone via email.

AML Patients Receiving PKC412 Midostaurin Show 23% OS Improvement in Phase III Trial 

 

Adult patients under 60 years of age with newly-diagnosed FLT3-mutated acute myeloid leukemia who received the investigational compound PKC412 (midostaurin), plus standard induction and consolidation chemotherapy, experienced a 23 percent improvement in overall survival (HR=0.77, p=0.0074), compared to those treated with standard induction and consolidation chemotherapy alone.

In the phase III RATIFY clinical trial, the median OS for patients in the PKC412 treatment group was 74.7 months (95% CI: 31.7, not attained), versus 25.6 months (95% CI: 18.6, 42.9) for patients in the placebo group.



To access this members-only content, please log in.

If you're not a subscriber why not join today?

If you believe you should be able to view this area but cannot log in, then please contact us and we will try to rectify this issue as soon as possible.


To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Letter